Novocure Ltd. (NASDAQ: NVCR), Zai Lab Ltd.’s (NASDAQ: ZLAB, HKG: 9688) Swiss oncology partner, announced FDA clearance for Optune Pax, its portable Tumor Treating Fields (TTFields) device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Phase III PANOVA-3 data demonstrated significant overall survival improvement (16.2 vs. 14.2 months) and pain-free survival benefit (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care in this high-mortality malignancy.
Innovative medical device pathway in China; NRDL negotiation for cancer supportive care category
Global Alignment
FDA approval validates technology; supports Zai Lab partnership valuation and ex-China rights discussions
Forward‑Looking Statements This brief contains forward‑looking statements regarding Optune Pax NMPA approval timelines in China, Zai Lab’s pancreatic cancer commercialization strategy, and TTFields market expansion in solid tumors. Actual results may differ due to regulatory review delays, physician adoption of device-based oncology therapy, and reimbursement negotiation outcomes for medical devices in China.-Fineline Info & Tech
Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.
